33.50

5.11% 1.63

After Hours: 33.50

Anaptysbio Inc (ANAB)

Overview News Price History Option Chain Financials Discussions Forecast

Anaptysbio Inc stock is traded at $33.50, with a volume of 348.54K. It is up +5.11% in the last 24 hours and down -12.05% over the past month. AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Previous Close:

$31.87

Open:

$31.59

24h Volume:

348.54K

Relative Volume:

1.12

Market Cap:

$1.01B

Revenue:

$17.16M

Net Income/Loss:

$-163.62M

P/E Ratio:

-6.4547

EPS:

-5.19

Net Cash Flow:

$-121.61M

1W Performance:

-5.82%

1M Performance:

-12.05%

6M Performance:

+48.76%

1Y Performance:

+86.53%

1-Day Range:

$31.59

$33.59

1-Week Range:

$31.55

$35.55

52-Week Range:

$13.36

$41.31

Anaptysbio Inc Stock (ANAB) Company Profile

Name

Anaptysbio Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

858-362-6295

Address

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Employee

117

Twitter

@anaptysbio

Next Earnings Date

2024-08-09

Latest SEC Filings

ANAB's Discussions on Twitter

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-23	Upgrade	JP Morgan	Underweight → Neutral
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Sep-13-22	Downgrade	Truist	Buy → Hold
Sep-01-22	Initiated	Raymond James	Outperform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy
May-21-21	Initiated	UBS	Neutral
Mar-16-21	Upgrade	Truist	Hold → Buy
Mar-09-21	Downgrade	Wedbush	Outperform → Neutral
Mar-08-21	Downgrade	JP Morgan	Overweight → Underweight
Feb-11-21	Upgrade	JP Morgan	Underweight → Overweight
Oct-27-20	Upgrade	Wedbush	Neutral → Outperform
Oct-14-20	Upgrade	Guggenheim	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Underweight
Nov-08-19	Downgrade	Jefferies	Buy → Hold
Nov-08-19	Downgrade	SunTrust	Buy → Hold
Nov-08-19	Downgrade	Wedbush	Outperform → Neutral
Jun-21-19	Downgrade	Credit Suisse	Outperform → Neutral
Jun-21-19	Downgrade	Stifel	Buy → Hold
Dec-20-18	Initiated	H.C. Wainwright	Buy
Nov-21-18	Initiated	JP Morgan	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Apr-04-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-27-18	Reiterated	Stifel	Buy
Mar-06-18	Reiterated	Stifel	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Jan-23-18	Reiterated	Credit Suisse	Outperform
Nov-15-17	Initiated	SunTrust	Buy
Nov-09-17	Initiated	Jefferies	Buy
Oct-11-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform

View All

Anaptysbio Inc Stock (ANAB) Latest News

09:00 AM

Anaptysbio BTLA agonist reduces atopic dermatitis inflammation - BioWorld Online

09:00 AM

Sep 29, 2024

Frazier Life Sciences Management L.P. Increases Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

Sep 29, 2024

Sep 28, 2024

(ANAB) On The My Stocks Page - Stock Traders Daily

Sep 28, 2024

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Ensign Peak Advisors Inc - MarketBeat

Sep 28, 2024

AnaptysBio, Inc. (NASDAQ:ANAB) Receives $51.10 Consensus Target Price from Analysts - MarketBeat

Sep 28, 2024

Sep 26, 2024

Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat

Sep 26, 2024

What Analysts Are Saying About AnaptysBio Stock - Benzinga

Sep 26, 2024

AnaptysBio Insiders Selling US$3.6m In Stock Relieved As Market Cap Slides To US$1.1b - Simply Wall St

Sep 26, 2024

Alpha DNA Investment Management LLC Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

Sep 26, 2024

Alpha DNA Investment Management LLC Invests $399,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

Sep 26, 2024

Sep 24, 2024

AnaptysBio chief medical officer sells shares worth over $58,000 By Investing.com - Investing.com Australia

Sep 24, 2024

AnaptysBio chief medical officer sells shares worth over $58,000 By Investing.com - Investing.com South Africa

Sep 24, 2024

AnaptysBio chief medical officer sells shares worth over $58,000 By Investing.com - Investing.com Canada

Sep 24, 2024

AnaptysBio chief medical officer sells shares worth over $58,000 - Investing.com

Sep 24, 2024

Daily Progress: Adaptive Biotechnologies Corp (ADPT) Drop -8.39, Closing at 4.26 - The Dwinnex

Sep 24, 2024

Applied Dna Sciences Inc (APDN) Stock: A Year of Market Fluctuations - The InvestChronicle

Sep 24, 2024

The ADPT Stock Puzzle: Unraveling Adaptive Biotechnologies Corp’s Fluctuating Performance - The InvestChronicle

Sep 24, 2024

APi Group Co. (NYSE:APG) Shares Sold by Progeny 3 Inc. - MarketBeat

Sep 24, 2024

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Position Reduced by First Light Asset Management LLC - MarketBeat

Sep 24, 2024

Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World

Sep 24, 2024

Sep 23, 2024

AnaptysBio (NASDAQ:ANAB) Shares Down 4.6% - MarketBeat

Sep 23, 2024

Market Watch: Applied Dna Sciences Inc (APDN)’s Noteworthy Gain, Closing at 1.25 - The Dwinnex

Sep 23, 2024

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat

Sep 23, 2024

Take off with AnaptysBio Inc (ANAB): Get ready for trading - SETE News

Sep 23, 2024

Applied Dna Sciences Inc (APDN) presents a great opportunity, but the stock is slightly overvalued - US Post News

Sep 23, 2024

Its Stock Has Paid Off Big Time For Andersons Inc. - SETE News

Sep 23, 2024